Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 20/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22121231 | 0.92 | STING1 (0.54) | STING1CYP3A4 | |
| SCHEMBL23095398 | 0.92 | STING1 (0.54) | STING1CYP3A4 | |
| SCHEMBL29437070 | 0.92 | STING1 (0.54) | STING1CYP3A4 | |
| SCHEMBL22925517 | 0.90 | STING1 (0.65) | STING1CYP3A4 | |
| SCHEMBL22121522 | 0.90 | STING1 (0.65) | STING1CYP3A4 | |
| SCHEMBL25098724 | 0.87 | STING1 (0.68) | STING1CYP3A4 | |
| SCHEMBL30206995 | 0.87 | STING1 (0.68) | STING1CYP3A4 | |
| SCHEMBL24611738 | 0.87 | STING1 (0.49) | STING1CYP3A4 | |
| SCHEMBL22121165 | 0.86 | STING1 (0.59) | STING1CYP3A4 | |
| SCHEMBL25098917 | 0.86 | STING1 (0.59) | STING1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-11713317-B2 | Tricyclic heterocyclic compounds as sting activators | INCYTE CORPORATION (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713317-B2 | Tricyclic heterocyclic compounds as sting activators | INCYTE CORPORATION (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713317-B2 | Tricyclic heterocyclic compounds as sting activators | INCYTE CORPORATION (US) | 2023-08-01 | — | — | US | disclosed |
| US-11596692-B1 | PD-L1/STING conjugates and methods of use | INCYTE CORPORATION (US) | 2023-03-07 | — | — | US | disclosed |
| US-11596692-B1 | PD-L1/STING conjugates and methods of use | INCYTE CORPORATION (US) | 2023-03-07 | — | — | US | disclosed |
| EP-3802534-B1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS | INCYTE CORP (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3802534-B1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS | INCYTE CORP (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20220073509-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS | INCYTE CORPORATION | 2022-03-10 | — | — | US | disclosed |
| US-20220073509-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS | INCYTE CORPORATION | 2022-03-10 | — | — | US | disclosed |
| EP-3802534-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS | Incyte Corporation (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10947227-B2 | Tricyclic heterocyclic compounds as sting activators | INCYTE CORPORATION (US) | 2021-03-16 | — | — | US | disclosed |
| US-10947227-B2 | Tricyclic heterocyclic compounds as sting activators | INCYTE CORPORATION (US) | 2021-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073509-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS | STING1, MAVS, IRF3 | STING1 1/4885CYP3A4 2421/4885 |
| US-11596692-B1 | PD-L1/STING conjugates and methods of use | STING1, PDCD1LG2, CD274 | STING1 1/4885CYP3A4 4862/4885 |
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | STING1, PDCD1LG2, CD274 | STING1 1/4885CYP3A4 4862/4885 |
| US-11713317-B2 | Tricyclic heterocyclic compounds as sting activators | STING1, MAVS, IRF3 | STING1 1/4885CYP3A4 2421/4885 |
| US-10947227-B2 | Tricyclic heterocyclic compounds as sting activators | STING1, MAVS, IRF3 | STING1 1/4885CYP3A4 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.